HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

armaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. Ortho Biotech Products L.P. and the Janssen-Cilag group of companies will be responsible for commercialization in the EU and the rest of the world. Janssen Pharmaceutical K.K. will be responsible for Japan.

"With a substantial clinical programme already underway, we look forward to further developing this unique and exciting compound and possibly help patients with other types of cancers," said Ken Watters, European Medical Director, Ortho Biotech.


'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... ... faculty and staff helped give free oral screenings to 150 children in kindergarten ... 2016. , The College of Dental Medicine joined Chinese American Dental Society of ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... yet the cause of injury may be one of many possible sources: sports, ... PT Continuing Education Course , Mastering Rehab Solutions for the Complexities of ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... treatment to Medicaid beneficiaries who are diagnosed with autism spectrum disorder (ASD). Beginning ... Autism treatment using applied behavior analysis (ABA) is key to providing effective ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products announces today an ... the StandUp Walker. Made entirely in the USA, the StandUp Walker is one ... StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of a stand-assist device ...
(Date:2/9/2016)... , ... February 09, 2016 ... ... and e-book publishing software, in partnership with Snowfall4pod Digital, creators of the ... comprehensive book publishing, content management, global distribution and print-on-demand network. , AVALANCHE ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Ill., Feb. 9, 2016  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for its fiscal 2016 first quarter ended December 31, ... Fiscal 2016 First Quarter Highlights , Revenue ... first quarter of 2015 , Domestic Radiation Measurement services ...
(Date:2/9/2016)... 2016 QGEN ; ... Abschluss eines Kooperationsvertrags mit 10x Genomics für ... den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology und Bioinformatik ... Prime Standard: QIA) gab heute den Abschluss ... Entwicklung und Förderung umfassender Lösungen in den ...
(Date:2/9/2016)... DIEGO , Feb. 9, 2016 Mast ... novel, clinical-stage therapies for sickle cell disease and heart failure, ... stock and warrants to purchase common stock in an underwritten ... conditions, and there can be no assurance as to whether ... the actual size or terms of the offering.   ...
Breaking Medicine Technology:
Cached News: